Predicting benefit from anti-angiogenic agents in malignancy.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 16837971.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A high probability of benefit is desirable to justify the choice of anti-angiogenic therapy from an ever-expanding list of expensive new anticancer agents. However, biomarkers of response to cytotoxic agents are not optimal for predicting benefit from anti-angiogenic drugs. This discussion will focus on both preclinical and clinical research to identify biomarkers for anti-angiogenic therapies that can inform dosing, early clinical benefit, initial drug choice, emerging resistance and second-line treatments.
Medical subject headings
- Angiogenesis Inhibitors
- Biomarkers, Tumor
- Neoplasms